icon-folder.gif   Conference Reports for NATAP  
 
  5th International Workshop on Hepatitis C
Resistance and New Compounds
24-25 June 2010, Boston, MA USA
Back grey_arrow_rt.gif
 
 
 
New HCV Protease: Preclinical Characteristics and Microdosing Pharmacokinetics in Healthy Volunteers Support a Low-Dose, Once-Daily Dosing Regimen of the HCV NS3/4a Protease Inhibitor ITMN-8187
 
 
  Ravi Rajagopalan
InterMune Inc., Brisbane, CA
 
Reported by Jules Levin
The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
Boston, MA June 23-24, 2010